Reducing attrition and maximizing ADC impact in metastatic breast cancer

touchIN CONVERSATION for touchONCOLOGY Identifying patients at risk of treatment attrition is an important part of treatment decision-making, as these patients may miss opportunities to receive subsequent treatments that could improve survival and quality of life. Listen to breast cancer experts consider the impact of treatment attrition in metastatic breast cancer and review evidence supporting the earlier integration of antibody–drug conjugates in the treatment pathway.   The experts Prof. Fatima Cardoso, Centre Antoine Lacassagne and Advanced Breast Cance (ABC) Global Alliance, Nice, France Asst. Prof. Domen Ribnikar, Institute of Oncology Ljubljana, Slovenia   This touchPODCAST is for HCPs outside of the UK.   This activity is supported by an independent medical education grant from Daiichi Sankyo Europe GmbH/AstraZeneca. touchIME is an EBAC® accredited provider.   For further information visit our website: www.touchONCOLOGY.com